News
NVO
48.88
-0.02%
-0.01
South African regulators issue recall of Ozempic copies
Reuters · 18h ago
Novo Nordisk Halts Device Study for CagriSema: What It Means for NVO Investors
TipRanks · 18h ago
Novo Nordisk Withdraws CagriSema Device Study, Nudging Investor Focus Back to Core Obesity Assets
TipRanks · 18h ago
Fundsmith adds AppLovin, TSMC, Uber; exits Nike, LVMH, Novo Nordisk among 1H moves
Seeking Alpha · 21h ago
Dr. Reddy's falls as quality issue delays supplies of Ozempic generic
Seeking Alpha · 22h ago
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
Seeking Alpha · 22h ago
Novo Nordisk: Why I Don't Think The Story Is Broken
Seeking Alpha · 23h ago
Hims and Hers (HIMS) Stock Still Has Upside, but Risks Persist
TipRanks · 1d ago
One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
Barchart · 1d ago
NOVO NORDISK <NOVOb.CO> LAUNCHES WORLD'S FIRST ONCE-WEEKLY BASAL INSULIN INJECTION AWIQLI IN INDIA - EXEC
Reuters · 1d ago
Fundsmith Equity Fund: H1 2026 Sales
Seeking Alpha · 1d ago
White House weighing contenders for FDA's top job
Seeking Alpha · 1d ago
Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With 21% Weight Loss Data
Simply Wall St · 1d ago
Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026
The Motley Fool · 1d ago
Novo Nordisk announces updated semaglutide label in Singapore
TipRanks · 2d ago
If I Could Only Buy Two High-Yield Stocks In July 2026
Seeking Alpha · 2d ago
Vivani Medical signs deal with Novo Nordisk to evaluate NPM-139 semaglutide implant
PUBT · 2d ago
3 Reasons to Buy Novo Nordisk Stock
The Motley Fool · 2d ago
Vivani Medical publishes investor presentation on NanoPortal long-acting GLP-1 implant pipeline for obesity
PUBT · 2d ago
Novo Nordisk Loses Its Edge, And I'm Downgrading
Seeking Alpha · 2d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.